In this article:

SVB Securities Thinks Connect Biopharma Holdings’ Stock is Going to Recover

In this article:
In this article:

In a report released today, Thomas Smith from SVB Securities maintained a Buy rating on Connect Biopharma Holdings (CNTBResearch Report), with a price target of $9.00. The company’s shares closed last Tuesday at $1.94, close to its 52-week low of $1.81.

According to TipRanks.com, Smith is ranked 0 out of 5 stars with an average return of -30.5% and a 12.6% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Eledon Pharmaceuticals, and Prometheus Biosciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Connect Biopharma Holdings.

See today’s best-performing stocks on TipRanks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307, CBP-174, and CBP-233.

Read More on CNTB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed